Our Company
Crystal Pharmatech, founded in 2010, is a global contract research organization with approximately 300 employees and four R&D centers in New Jersey (USA), San Francisco (USA), Toronto (Canada), and Suzhou (China). Collectively, these sites provide integrated support for pharmaceutical and biotechnology companies worldwide. Our capabilities span three specialized platforms: in small molecules, we offer API solid-state research and crystallization, preformulation, formulation development, and GMP manufacturing and supply; under Crystal Bio Solutions, we deliver bioanalytical and biomarker testing, biologics CMC analytics, and clinical pharmacology.
With an average of 20 years of experience, our scientific leadership team has successfully delivered over 100 NCEs and 15 drug products for global pharmaceutical companies. We have served over 1,000 clients, supporting more than 2,000 new chemical entities.
Leveraging our unique expertise, we collaborate with you to design and develop the most suitable crystal form and formulation for further development. Our guiding principle of "getting the crystal form and formulation right the first time for Phase I" not only expedites the progression of your molecule to IND filing and Phase I clinical trials, but also minimizes the necessity for human PK bridging studies. This approach saves valuable time and reduces costs as your program moves forward to Phase II or subsequent clinical trials.
